James P Daubert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6997054/publications.pdf Version: 2024-02-01



INMES P DALIBERT

#	Article	IF	CITATIONS
1	Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. New England Journal of Medicine, 2002, 346, 877-883.	27.0	6,199
2	Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular Arrhythmia. New England Journal of Medicine, 1996, 335, 1933-1940.	27.0	3,859
3	Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. New England Journal of Medicine, 2009, 361, 1329-1338.	27.0	2,716
4	Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy. New England Journal of Medicine, 2004, 350, 2151-2158.	27.0	1,840
5	Reduction in Inappropriate Therapy and Mortality through ICD Programming. New England Journal of Medicine, 2012, 367, 2275-2283.	27.0	1,186
6	Inappropriate Implantable Cardioverter-Defibrillator Shocks in MADIT II. Journal of the American College of Cardiology, 2008, 51, 1357-1365.	2.8	735
7	Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT). Circulation, 2011, 123, 1061-1072.	1.6	714
8	Long-Term Clinical Course of Patients After Termination of Ventricular Tachyarrhythmia by an Implanted Defibrillator. Circulation, 2004, 110, 3760-3765.	1.6	538
9	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16, e301-e372.	0.7	494
10	The Clinical Implications of Cumulative Right Ventricular Pacing in the Multicenter Automatic Defibrillator Trial II. Journal of Cardiovascular Electrophysiology, 2005, 16, 359-365.	1.7	298
11	Are Implantable Cardioverter Defibrillator Shocks a Surrogate for Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy?. Circulation, 2006, 113, 776-782.	1.6	279
12	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm, 2016, 13, e50-e86.	0.7	197
13	Initial Independent Outcomes from Focal Impulse and Rotor Modulation Ablation for Atrial Fibrillation: Multicenter FIRM Registry. Journal of Cardiovascular Electrophysiology, 2014, 25, 921-929.	1.7	179
14	Venous Thrombosis and Stenosis After Implantation of Pacemakers and Defibrillators. Journal of Interventional Cardiac Electrophysiology, 2005, 13, 9-19.	1.3	178
15	Predictive Value of Ventricular Arrhythmia Inducibility for Subsequent Ventricular Tachycardia or Ventricular Fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II Patients. Journal of the American College of Cardiology, 2006, 47, 98-107.	2.8	167
16	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm, 2019, 16, e373-e407.	0.7	135
17	Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. European Heart Journal, 2011, 32, 1622-1630.	2.2	128
18	Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. Heart Rhythm, 2018, 15, 651-657.	0.7	102

#	Article	IF	CITATIONS
19	Mortality Reduction in Relation to Implantable Cardioverter Defibrillator Programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circulation: Arrhythmia and Electrophysiology, 2014, 7, 785-792.	4.8	101
20	PR Interval Identifies Clinical Response in Patients With Non–Left Bundle Branch Block. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 645-651.	4.8	98
21	Risk of atrioesophageal fistula formation with contact force–sensing catheters. Heart Rhythm, 2017, 14, 1328-1333.	0.7	91
22	Impaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and LeftÂBundle Branch Block. Journal of the American College of Cardiology, 2018, 71, 306-317.	2.8	71
23	The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling. European Heart Journal, 2015, 36, 440-448.	2.2	68
24	Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. European Heart Journal, 2021, 42, 1676-1684.	2.2	61
25	Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT. European Heart Journal, 2014, 35, 106-115.	2.2	57
26	Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators. Journal of the American College of Cardiology, 2018, 72, 636-645.	2.8	55
27	Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy. American Heart Journal, 2017, 189, 75-84.	2.7	52
28	Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. Heart Rhythm, 2006, 3, 631-637.	0.7	51
29	Association Between Frequency of Atrial and Ventricular Ectopic Beats and Biventricular Pacing Percentage and Outcomes in Patients With Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2014, 64, 971-981.	2.8	50
30	Race and gender variation in the QT interval and its association with mortality in patients with coronary artery disease: Results from the Duke Databank for Cardiovascular Disease (DDCD). American Heart Journal, 2012, 164, 434-441.	2.7	49
31	New Concepts in Sudden Cardiac Arrest to AddressÂan Intractable Epidemic. Journal of the American College of Cardiology, 2019, 73, 70-88.	2.8	42
32	Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome. American Heart Journal, 2007, 153, 53-58.	2.7	40
33	Multiple Comorbidities and Response to Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2017, 69, 2369-2379.	2.8	37
34	Multicenter Automatic Defibrillator Implantation Trial: Reduce Inappropriate Therapy (MADITâ€RIT): Background, Rationale, and Clinical Protocol. Annals of Noninvasive Electrocardiology, 2012, 17, 176-185.	1.1	36
35	Incidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation. American Journal of Cardiology, 2017, 119, 1017-1022.	1.6	36
36	Cable externalization and electrical failure of the Riata family of implantable cardioverter-defibrillator leads: A systematic review and meta-analysis. Heart Rhythm, 2015, 12, 1233-1240.	0.7	35

#	Article	IF	CITATIONS
37	Ventricular Arrhythmia Inducibility Predicts Subsequent ICD Activation in Nonischemic Cardiomyopathy Patients: A DEFINITE Substudy. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 755-761.	1.2	34
38	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverterâ€defibrillator programming and testing. Journal of Arrhythmia, 2016, 32, 1-28.	1.2	34
39	Association Between a Prolonged PR Interval and Outcomes of Cardiac Resynchronization Therapy. Circulation, 2016, 134, 1617-1628.	1.6	33
40	Multicenter Automatic Defibrillator Implantation Trial–Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. American Heart Journal, 2017, 189, 158-166.	2.7	31
41	The Effect of Intermittent Atrial Tachyarrhythmia on Heart Failure or Death inÂCardiac Resynchronization Therapy WithÂDefibrillator Versus Implantable Cardioverter-Defibrillator Patients. Journal of the American College of Cardiology, 2014, 63, 1190-1197.	2.8	28
42	Dofetilide dose reductions and discontinuations in women compared with men. Heart Rhythm, 2018, 15, 478-484.	0.7	28
43	Ventricular Tachycardia Induced Cardiomyopathy: Improvement with Radiofrequency Ablation. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 505-508.	1.2	27
44	Outcomes 1 Year After Implantable Cardioverter–Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	25
45	Novel ICD Programming and Inappropriate ICD Therapy in CRT-D Versus ICD Patients. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e001965.	4.8	25
46	Comparison of Incidence of Left Ventricular Systolic Dysfunction Among Patients With Left Bundle Branch Block Versus Those With Normal QRS Duration. American Journal of Cardiology, 2017, 120, 1990-1997.	1.6	24
47	Clinical outcome as a function of the PR-intervalthere is virtue in moderation: data from the Duke Databank for cardiovascular disease. Europace, 2015, 17, 978-985.	1.7	22
48	Subcutaneous implantable cardioverter-defibrillator troubleshooting in patients with a left ventricular assist device: A case series and systematic review. Heart Rhythm, 2020, 17, 1536-1544.	0.7	21
49	Survival After Implantable Cardioverter-Defibrillator Shocks. Journal of the American College of Cardiology, 2021, 77, 2453-2462.	2.8	20
50	Firstâ€Ðegree AV Block—An Entirely Benign Finding or a Potentially Curable Cause of Cardiac Disease?. Annals of Noninvasive Electrocardiology, 2013, 18, 215-224.	1.1	19
51	Novel mechanism of premature battery failure due to lithium cluster formation in implantable cardioverter-defibrillators. Heart Rhythm, 2014, 11, 2190-2195.	0.7	19
52	Adverse outcomes associated with postoperative atrial arrhythmias after lung transplantation: A metaâ€analysis and systematic review of the literature. Clinical Transplantation, 2017, 31, e12926.	1.6	19
53	Left bundle branch block-induced left ventricular remodeling and its potential for reverse remodeling. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 343-352.	1.3	19
54	Catheter ablation for ventricular tachycardia (VT) in patients with ischemic heart disease: a systematic review and a meta-analysis of randomized controlled trials. Journal of Interventional Cardiac Electrophysiology, 2016, 45, 111-117.	1.3	18

#	Article	IF	CITATIONS
55	Recurrent Post-Ablation Paroxysmal AtrialÂFibrillation Shares Substrates WithÂPersistent Atrial Fibrillation. JACC: Clinical Electrophysiology, 2017, 3, 393-402.	3.2	18
56	Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation. American Heart Journal, 2020, 220, 89-96.	2.7	18
57	Identification of Undetected Monogenic Cardiovascular Disorders. Journal of the American College of Cardiology, 2020, 76, 797-808.	2.8	17
58	Periprocedural imaging and outcomes after catheter ablation of atrial fibrillation. Heart, 2014, 100, 1871-1877.	2.9	16
59	Leadless pacemaker implantation after lead extraction for cardiac implanted electronic device infection. Journal of Cardiovascular Electrophysiology, 2022, 33, 464-470.	1.7	16
60	Catheter ablation of atrial fibrillation in cardiac amyloidosis. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 913-921.	1.2	14
61	Performance of a New Cardiac Cryoablation System in the Treatment of Cavotricuspid Valve Isthmus-Dependent Atrial Flutter. PACE - Pacing and Clinical Electrophysiology, 2005, 28, S142-S145.	1.2	13
62	Cryoablation of atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2011, 32, 233-242.	1.3	13
63	Adverse Effects of Firstâ€Degree AVâ€Block in Patients with Sinus Node Dysfunction: Data from the Mode Selection Trial. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 1111-1119.	1.2	12
64	Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapyâ€defibrillator patients: a <scp>MADIT</scp> â€ <scp>CRT</scp> substudy. Annals of Noninvasive Electrocardiology, 2018, 23, e12491.	1.1	12
65	Reassessing the role of antitachycardia pacing in fast ventricular arrhythmias in primary prevention implantable cardioverter-defibrillator recipients: Results from MADIT-RIT. Heart Rhythm, 2021, 18, 399-403.	0.7	12
66	Arrhythmic and Mortality Outcomes Among Ischemic Versus Nonischemic Cardiomyopathy Patients Receiving Primary ICD Therapy. JACC: Clinical Electrophysiology, 2022, 8, 1-11.	3.2	12
67	Predicting atrial fibrillation recurrence after ablation in patients with heart failure: Validity of the APPLE and CAAPâ€AF risk scoring systems. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1440-1447.	1.2	11
68	Catheter ablation of atrial fibrillation in patients with diabetes mellitus. Heart Rhythm O2, 2020, 1, 180-188.	1.7	11
69	High and Low Strength Nonsynchronized Shocks Given During Canine Ventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 986-992.	1.2	10
70	Implantable Cardioverterâ€Defibrillators for Primary Prevention: How Do the Data Pertain to the Aged?. The American Journal of Geriatric Cardiology, 2006, 15, 88-92.	0.6	10
71	ECG myocardial scar quantification predicts reverse left ventricular remodeling and survival after cardiac resynchronization therapy implantation: A retrospective pilot study. Journal of Electrocardiology, 2015, 48, 565-570.	0.9	10
72	Temporal Trends in and FactorsÂAssociated With Use of Single-ÂVersusÂDual-Coil Implantable Cardioverter-Defibrillator Leads. JACC: Clinical Electrophysiology, 2017, 3, 612-619.	3.2	10

#	Article	IF	CITATIONS
73	Electrical storm in patients with left ventricular assist devices: Risk factors, incidence, and impact on survival. Heart Rhythm, 2021, 18, 1263-1271.	0.7	10
74	Antiarrhythmic Agents in Older Patients. Drugs and Aging, 1994, 4, 462-469.	2.7	9
75	Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease. Europace, 2014, 16, 1284-1290.	1.7	9
76	Comparison of Safety of Sotalol Versus Amiodarone inÂPatients With Atrial Fibrillation and Coronary Artery Disease. American Journal of Cardiology, 2014, 114, 716-722.	1.6	9
77	Atrial fibrillation ablation alone or atrial fibrillation ablation plus an antiarrhythmic drug?. European Heart Journal, 2018, 39, 1438-1441.	2.2	9
78	Obstructive sleep apnea is associated with increased rotor burden in patients undergoing focal impulse and rotor modification guided atrial fibrillation ablation. Europace, 2018, 20, f337-f342.	1.7	9
79	Scar burden assessed by Selvester QRS score predicts prognosis, not CRT clinical benefit in preventing heart failure event and death: A MADIT-CRT sub-study. Journal of Electrocardiology, 2016, 49, 603-609.	0.9	8
80	Sex Differences in Inappropriate ICD Device Therapies: MADITâ€II and MADIT RT. Journal of Cardiovascular Electrophysiology, 2017, 28, 94-102.	1.7	8
81	Atrial Fibrillation and Sudden Cardiac Death. JACC: Heart Failure, 2014, 2, 228-229.	4.1	7
82	Reduction in Inappropriate ICD Therapy in MADITâ€RIT Patients Without History of Atrial Tachyarrhythmia. Journal of Cardiovascular Electrophysiology, 2015, 26, 879-884.	1.7	7
83	Localization of pacing and defibrillator leads using standard x-ray views is frequently inaccurate and is not reproducible. Journal of Interventional Cardiac Electrophysiology, 2015, 43, 5-12.	1.3	7
84	Ranolazine reduces atrial fibrillatory wave frequency. Europace, 2016, 19, euw200.	1.7	7
85	Prevalence of atrial fibrillation and association with clinical, sociocultural, and ancestral correlates among Hispanic/Latinos: The Hispanic Community Health Study/Study of Latinos. Heart Rhythm, 2019, 16, 686-693.	0.7	7
86	Interleukin-1β gene variants are associated with QTc interval prolongation following cardiac surgery: a prospective observational study. Canadian Journal of Anaesthesia, 2016, 63, 397-410.	1.6	6
87	Heart failure severity, inappropriate ICD therapy, and novel ICD programming: a MADITâ€RIT substudy. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 1405-1411.	1.2	5
88	Death with an implantable cardioverter-defibrillator: a MADIT-II substudy. Europace, 2019, 21, 1843-1850.	1.7	5
89	Cardiovascular Implantable Electronic Device Surgery Following Left Ventricular Assist Device Implantation. JACC: Clinical Electrophysiology, 2020, 6, 1131-1139.	3.2	5
90	Novel Insights Into Beta-Blocker Therapy for Long QT Syndromes. Journal of the American College of Cardiology, 2012, 60, 2100-2102.	2.8	4

#	Article	IF	CITATIONS
91	Catheter Ablation of Mid-Myocardial Ventricular Tachycardia by Simultaneous Unipolar Radiofrequency Ablation With Half-Normal Saline Irrigation. JACC: Clinical Electrophysiology, 2018, 4, 1263-1264.	3.2	4
92	Lead Extraction for Cardiovascular Implantable Electronic Device Infection in Patients With Left Ventricular Assist Devices. JACC: Clinical Electrophysiology, 2020, 6, 672-680.	3.2	4
93	Assessment of primary prevention patients receiving an ICD – Systematic evaluation of ATP: APPRAISE ATP. Heart Rhythm O2, 2021, 2, 405-411.	1.7	4
94	Underutilization of Implantable Cardioverter Defibrillator in Primary Prevention of Sudden Cardiac Arrest. Cardiology Research, 2011, 2, 1-6.	1.1	4
95	2021 HRS Educational Framework for Clinical Cardiac Electrophysiology. Heart Rhythm O2, 2022, 3, 120-132.	1.7	4
96	Response to Letter Regarding, "PR Interval Identifies Clinical Response in Patients With Non-Left Bundle Branch Block: A Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy Sub-Study―by Kutyifa et al. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 1280-1280.	4.8	3
97	Smarter Deployment of Implantable Cardioverter-Defibrillators in Nonischemic Cardiomyopathy. Journal of the American College of Cardiology, 2014, 63, 1890-1891.	2.8	3
98	Left Bundle Branch Block. JACC: Heart Failure, 2016, 4, 904-906.	4.1	3
99	Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Cardiomyopathy. JACC: Heart Failure, 2019, 7, 725-727.	4.1	3
100	On the Trail of Ventricular Tachycardia or the Adventure of the Unspeckled Band. PACE - Pacing and Clinical Electrophysiology, 1988, 11, 650-655.	1.2	2
101	Editorial Commentary: Prevention and treatment of atrial fibrillation: Is hyperuricemia the next target?. Trends in Cardiovascular Medicine, 2019, 29, 48-49.	4.9	2
102	Head-Up Tilt-Table Testing: An Overview. Annals of Noninvasive Electrocardiology, 1999, 4, 212-218.	1.1	1
103	If Some Primary Prevention Implantable Cardioverter-Defibrillator Implants AreÂFutile, Can We Identify Them A Priori?. JACC: Clinical Electrophysiology, 2015, 1, 38-40.	3.2	1
104	Antitachycardia pacing for termination of ventricular tachyarrhythmias: should we use it?. Europace, 2015, 17, 1005-1006.	1.7	1
105	Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators. Cardiac Electrophysiology Clinics, 2015, 7, 695-707.	1.7	1
106	Fragmentation and defragmenting: How to ablate in the age of connectivity?. Heart Rhythm, 2017, 14, 41-42.	0.7	1
107	Effectiveness of high rate and delayed detection ICD programming by race: A MADITâ€RIT substudy. Journal of Cardiovascular Electrophysiology, 2018, 29, 1418-1424.	1.7	1
108	Prognostication for Sudden Cardiac Arrest Patients Achieving ROSC. Journal of the American College of Cardiology, 2021, 77, 372-374.	2.8	1

#	Article	IF	CITATIONS
109	Editorial commentary: Pulsed field catheter ablation in atrial fibrillation: The promising future of an old technology. Trends in Cardiovascular Medicine, 2022, 32, 388-389.	4.9	1
110	Acute echocardiographic and hemodynamic response to hisâ€bundle pacing in patients with firstâ€degree atrioventricular block. Annals of Noninvasive Electrocardiology, 2022, , e12954.	1.1	1
111	Nonsustained Ventricular Tachycardia Annals of Noninvasive Electrocardiology, 1997, 2, 79-91.	1.1	Ο
112	More Bad News for Cardiac Resynchronization Therapy in Atrial Fibrillation Patients: What to Do?. Journal of Cardiovascular Electrophysiology, 2013, 24, 1123-1124.	1.7	0
113	Permanent Hisâ€Bundle Pacing: An Adolescent with Promise. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 1290-1293.	1.2	0
114	Editorial commentary: Atrial fibrillation ablation with cryoenergy: It׳s "Coolâ€; it׳s "Non-inferiorâ€; Is it better?. Trends in Cardiovascular Medicine, 2017, 27, 278-279.	4.9	0
115	Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators. Heart Failure Clinics, 2017, 13, 139-151.	2.1	Ο
116	Do new tools help us identify substrate to target for ablation in ventricular tachycardia?. Journal of Cardiovascular Electrophysiology, 2017, 28, 1068-1069.	1.7	0
117	How to Perform Pacemaker Troubleshooting. , 2017, , 173-186.		0
118	Reply. Journal of the American College of Cardiology, 2018, 71, 1945-1946.	2.8	0
119	Editorial commentary: Sleeping on a treatment for atrial fibrillation?. Trends in Cardiovascular Medicine, 2021, 31, 133-134.	4.9	Ο
120	Abstract 9920: Outcomes Associated With Lead Abandonment versus Lead Extraction Strategies for Revision of Sterile Leads: An NCDR® Analysis. Circulation, 2015, 132, .	1.6	0
121	Abstract 17673: The Effectiveness of Improved ICD Programming by Race: A MADIT-RIT Sub-study. Circulation, 2015, 132, .	1.6	0